quinacrine has been researched along with asulacrine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Baguley, BC; Finlay, GJ; Wilson, WR | 1 |
| Baguley, BC; Ching, LM; Darkin, SJ; Lawson, PA; Ralph, RK; Schneider, E | 1 |
3 other study(ies) available for quinacrine and asulacrine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
Topics: Aminacrine; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Colony-Forming Units Assay; Intercalating Agents; Isomerism; Leukemia P388; Mice; Quinacrine; Topoisomerase II Inhibitors; Tumor Stem Cell Assay | 1989 |
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
Topics: Acridines; Aminacrine; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Mice; Neoplasm Proteins; Quinacrine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1988 |